Tech Company Financing Transactions
Horizon Pharma Funding Round
Scale Venture Partners, FirstMark Capital and Sutter Hill Ventures participated in a $15 million Series B capital raise for Horizon Pharma. The round closed on 1/4/2007.
Transaction Overview
Company Name
Announced On
1/4/2007
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series B
Investors
Proceeds Purpose
Funding will be used to advance its lead product HZT-501, a "GI-friendly" prescription NSAID, into pivotal Phase 3 clinical trials in the first half of this year.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
150 South Wacker Dr. 3200
Chicago, IL 60606
USA
Chicago, IL 60606
USA
Phone
Website
Email Address
Overview
A company passionate about improving the treatment of arthritis and pain for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Walbert
Chief Financial Officer
Paul Hoelscher
Chief Medical Officer
Jeffrey Sherman
Chief Scientific Officer
Shao-Lee Lin
VP - Administration
Barry Moze
VP - Bus. Development
Robert Carey
VP - General Counsel
Brian Beeler
VP - Human Resources
Irina Konstantinovsky
Browse more venture capital transactions:
Prev: 1/4/2007: Next New Networks venture capital transaction
Next: 1/5/2007: Senior Whole Health venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs